Veracyte (VCYT) Enterprise Value (2012 - 2026)

Veracyte has reported Enterprise Value for 15 years, with the latest figure at -$299.5 million in Q2 2026.

• Enterprise Value for Q2 2026 came in at -$299.5 million, down 36.46% year-over-year; the trailing twelve-month figure through Jun 2026 was -$299.5 million (down 36.46% YoY), and the FY2025 annual result was -$362.6 million, down 51.65% from the prior year.
• Enterprise Value slipped to -$299.5 million in Q2 2026, from -$263.1 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$153.4 million in Q2 2022 and troughed at -$362.6 million in Q4 2025.
• A 5-year average of -$224.1 million and a median of -$212.8 million in 2023 frame the typical range for Enterprise Value.
• The widest annual swing landed in 2022, when Enterprise Value soared 53.15%; it then tumbled 51.65% in 2025.
• A 5-year view of Enterprise Value shows it stood at -$154.2 million in 2022, then plunged by 40.33% to -$216.5 million in 2023, then decreased by 10.46% to -$239.1 million in 2024, then sank by 51.65% to -$362.6 million in 2025, then climbed by 17.39% to -$299.5 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$299.5 million in Q2 2026, -$263.1 million in Q1 2026, and -$362.6 million in Q4 2025.